{"title":"STANDARDIZE QC PROCEDURE FOR SCRNA-SEQ","authors":"Shansha Peng , Chunyu Liu","doi":"10.1016/j.euroneuro.2024.08.025","DOIUrl":null,"url":null,"abstract":"<div><div>Single-cell RNA sequencing (scRNA-seq) has emerged as a pivotal technology for dissecting cellular heterogeneity and function. In an effort to assess the consistency and rigor of quality control (QC) measures across scRNA-seq studies, we systematically reviewed publications from high-impact journals, including Cell, Nature, Science, and their major sister journals. Our analysis revealed a lack of standardization in QC procedures, with significant variability in the parameters employed. Despite general agreement on the necessity of certain QC steps, such as the removal of low-quality cells and the detection of doublets, the specific criteria for these steps were often arbitrarily defined and not universally applied. Notably, the assessment of ambient RNA contamination and the precision of gene expression measurements were frequently overlooked, potentially leading to the inclusion of spurious data in downstream analyses. To address these inconsistencies, we propose a revised set of QC procedures and parameters, which yielded distinct results compared to the original publications when applied to existing datasets. Moreover, we also assessed the performance of the existing data-driven QC tools in distinguishing the low-quality cells from the high-quality cells. Our findings underscore the urgent need for a standardized approach to QC in scRNA-seq to ensure the reliability and reproducibility of biological insights derived from this powerful technology.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"87 ","pages":"Page 9"},"PeriodicalIF":6.1000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0924977X24002244","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Single-cell RNA sequencing (scRNA-seq) has emerged as a pivotal technology for dissecting cellular heterogeneity and function. In an effort to assess the consistency and rigor of quality control (QC) measures across scRNA-seq studies, we systematically reviewed publications from high-impact journals, including Cell, Nature, Science, and their major sister journals. Our analysis revealed a lack of standardization in QC procedures, with significant variability in the parameters employed. Despite general agreement on the necessity of certain QC steps, such as the removal of low-quality cells and the detection of doublets, the specific criteria for these steps were often arbitrarily defined and not universally applied. Notably, the assessment of ambient RNA contamination and the precision of gene expression measurements were frequently overlooked, potentially leading to the inclusion of spurious data in downstream analyses. To address these inconsistencies, we propose a revised set of QC procedures and parameters, which yielded distinct results compared to the original publications when applied to existing datasets. Moreover, we also assessed the performance of the existing data-driven QC tools in distinguishing the low-quality cells from the high-quality cells. Our findings underscore the urgent need for a standardized approach to QC in scRNA-seq to ensure the reliability and reproducibility of biological insights derived from this powerful technology.
期刊介绍:
European Neuropsychopharmacology is the official publication of the European College of Neuropsychopharmacology (ECNP). In accordance with the mission of the College, the journal focuses on clinical and basic science contributions that advance our understanding of brain function and human behaviour and enable translation into improved treatments and enhanced public health impact in psychiatry. Recent years have been characterized by exciting advances in basic knowledge and available experimental techniques in neuroscience and genomics. However, clinical translation of these findings has not been as rapid. The journal aims to narrow this gap by promoting findings that are expected to have a major impact on both our understanding of the biological bases of mental disorders and the development and improvement of treatments, ideally paving the way for prevention and recovery.